Standard pre‑examination protocol – must be demonstrated:
Action: Introduce yourself, explain the examination, and obtain verbal consent.
Key observations – “Floppy infant” clues:
Systematic neuromuscular exam – “180° examination” sequence:
Systematic examination:
Assess:
📋 Case Presentation – (fill in during exam)
This is a _____-month-old _____ child, referred for _____ (hypotonia / weakness / feeding difficulties). On examination, the child appears _____ (alert / lethargic), with _____ (frog‑leg posture / normal). Cranial nerves: _____ (tongue fasciculations / ptosis / normal). Tone: _____ (profoundly hypotonic / normal). Power: _____ (poor antigravity / preserved). Reflexes: _____ (absent / brisk / normal). Primitive reflexes: _____ (Moro absent / present). Respiratory: _____ (paradoxical breathing / normal). Growth: weight _____ percentile, length _____ percentile, head circumference _____ percentile. Associated signs: _____ (contractures / dysmorphism / hepatomegaly).
• Spinal muscular atrophy (SMA) type 1 – areflexia, tongue fasciculations, frog‑leg posture
• Congenital myopathies (nemaline, central core) – weakness, normal CK
• Congenital muscular dystrophy – elevated CK, contractures
• Congenital myotonic dystrophy – maternal history, myopathic facies
• Infantile botulism – descending paralysis, constipation, ptosis
• Metabolic myopathies – Pompe (cardiomegaly), GSD, mitochondrial
• Central hypotonia – CP, Down, Prader‑Willi (normal reflexes, dysmorphic)
• Neuromuscular junction – transient neonatal myasthenia, congenital myasthenic syndrome
• Peripheral neuropathy – Charcot‑Marie‑Tooth, congenital hypomyelinating
• Genetic testing: SMA (SMN1 deletion) – first line.
• Creatine kinase (CK): normal in SMA, elevated in dystrophies.
• Electromyography (EMG): neurogenic (SMA) vs myopathic (myopathies).
• Nerve conduction studies: normal in SMA, slow in neuropathies.
• Muscle biopsy: for congenital myopathies, metabolic disorders.
• Brain MRI: if central cause suspected.
• SMA gene testing: SMN1 homozygous deletion (95%).
• Metabolic screen: lactate, ammonia, amino acids, acylcarnitine.
• TORCH: if congenital infection suspected.
• Chromosomes: Prader‑Willi (FISH for 15q11‑13).
• Maternal history: myotonic dystrophy, myasthenia gravis.
• Brain MRI: to exclude structural/central causes.
• Lumbar puncture: if infection (botulism, meningitis).
• Echocardiogram: if Pompe or mitochondrial suspected.
• EMG/NCS: to differentiate myopathy vs neuropathy vs NMJ.
• Pulmonary function: FVC, sleep study (SMA, myopathies).
• Swallow study: aspiration risk (bulbar weakness).
• ECG/ECHO: cardiomyopathy (myotonic dystrophy, mitochondrial).
• Orthopedic: X‑ray for scoliosis, hip dislocation.
• Genetic counselling: recurrence risk, prenatal diagnosis.
🔹 Management – Across Organ Systems
Non‑invasive ventilation (BiPAP), cough assist, chest physiotherapy. Avoid respiratory infections.
High‑calorie feeds, NG tube or gastrostomy for dysphagia. Monitor for aspiration.
Physiotherapy, stretching, splints; manage scoliosis, hip dislocation.
SMA: nusinersen, risdiplam, gene therapy. Myotonic: mexiletine for myotonia. Myasthenia: pyridostigmine.
Discuss prognosis, advanced care planning, support for family.
Neurology, respiratory, genetics, physiotherapy, occupational therapy, dietitian, social work.
📈 Prognosis
📋 Follow‑up Schedule